Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report

• DOI: 10.3389/fonc.2024.1401882
• Publication Date: 2024-05-16T11:06:30Z
• Authors: Xin Jiang; Afaf Aljbri; Jiaxuan Liu; Liqi Shang; Yulong Tian; Haibo Shao
• Keywords: FOLFOX; Hepatic arterial infusion; Regimen; Liver Cancer

Hepatocellular carcinoma (HCC) is a common gastrointestinal malignancy characterized by high incidence rates and poor prognosis. Common treatment modalities include surgery, ablation, transarterial chemoembolization (TACE). Hepatic arterial infusion chemotherapy (HAIC) has long been used in the of unresectable liver cancer. In recent years, combination anti-angiogenesis therapy immune checkpoint inhibitors shown significant advances middle- advanced-stage This report presents case HCC which sustained benefits are achieved through HAIC infusional oxaliplatin, leucovorin, fluorouracil (FOLFOX), targeted therapy, immunotherapy.